Back to Top
  • We are Certified Personal Trainer’s

  • Do Work That Aligns with your Heart

  • A Fresh Approach To Health & Life


Zinc Orotate: Uses,Dosage,Side Effects

Generic Name
Zinc Orotate
Therapeutic Group: Zinc Supplement

Indications:
Oral zinc therapy is indicated in zinc deficiency and/or zinc losing conditions like-Hair loss,, Skin rashes, Major depression, Loss of smell, taste, and memory, White spots on the fingernails, Increased susceptibility to infection, Loss of activity of growth hormone (GH), Adults: One tablet twice daily with a meal. Visual impairment, Hypogonadism, Diarrhea, Male infertility, Sickle cell anemia, Delayed wound healing, Type 2- diabetes.

Presentation:
Zinc Orotate Tablet: Each tablet contains Zinc Orotate INN 60 mg including elemental zinc 9.5 mg.

Description:
Zinc Orotate is a preparation of Zinc Orotate which is a chelated form of zinc found in the human body in trace amounts. Zinc is one of the most essential elements as per body requirement. Orotate (the mineral salt of orotic acid) is a biochemical substance made by all living cells. It is a necessary raw material for making the genetic material: RNA and DNA. Orotic acid assists the transport of zinc through cellular membrane structures, facilitating the intracellular uptake of zinc. Zinc orotate has increased bioavailability over other forms of zinc because of its chelated form.

Dosage & Administration:
Adults: One tablet twice daily with a meal.

Side Effects:
Zinc might cause nausea, vomiting, metallic taste and stomach upset, etc.

Precautions:
Patients with diabetes & acute renal failure should use zinc products cautiously.

Use in Pregnancy & Lactation:
It should be used in pregnant or lactating mothers after consultation with a health care professional.

Drug Interaction:
Concomitant intake of tetracycline, quinolone, and penicillamine along with zinc may decrease the absorption of both drugs.

Overdose:
Taking doses higher than 40 mg (elemental zinc) daily might cause fever, cough, upset stomach.

Storage:
Store in a cool and dry place, away from light & moisture. Keep out of the reach of children.

Zoledronic Acid One bottle with 5 mg/100 ml

Generic Name
Zoledronic Acid
Therapeutic Group: Bone and Joint Disorder

Presentation:
Zoledronic acid solution for infusion: One bottle with 100 ml solution contains Zoledronic acid INN 5 mg.

Description:
Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic acid is rapidly distributed to the bone. The main molecular target of Zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase, but this does not exclude other mechanisms. There was no accumulation of the active substance in plasma after multiple doses are given every 28 days. Zoledronic acid is not metabolized and is excreted unchanged via the kidney.

Indications:
Zoledronic acid is indicated for the treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures; prevention of clinical fractures after a hip fracture; treatment and prevention of glucocorticoid-induced osteoporosis; treatment of osteoporosis in men and for the treatment of Paget's disease of bone. Treatment should be restricted to three annual doses.

Dosage & Administration:
Treatment of postmenopausal osteoporosis
The recommended dose is a single intravenous infusion of 5 mg Zoledronic acid administered once a year. Adequate supplemental Calcium and Vitamin-D intake is important in women with osteoporosis if dietary intake is inadequate.

Prevention of clinical fractures after a hip fracture
The recommended dose is a single intravenous infusion of 5 mg Zoledronic acid administered once a year. In patients with a recent low-trauma hip fracture, it is recommended to give the first Zoledronic acid solution for infusion two or more weeks after hip fracture repairs. It is also recommended to have a loading dose of 50,000 to 125,000 IU of Vitamin-D given orally or via intramuscular route prior to the first administration of Zoledronic acid solution for infusion. Supplemental Calcium and Vitamin-D intake is recommended for patients treated to prevent clinical fractures after a hip fracture.

Treatment of osteoporosis in men
Recommended dose is a single intravenous infusion of 5 mg Zolenic administered once a year. Adequate supplemental Calcium and Vitamin-D intake is important in men with osteoporosis if dietary intake is inadequate.

Treatment and prevention of glucocorticoid-induced osteoporosis
The recommended dose is a single intravenous infusion of 5 mg Zoledronic acid administered once a year. Adequate supplemental Calcium and Vitamin-D intake is important in patients with osteoporosis if dietary intake is inadequate.

Treatment of Paget's disease of bone
The recommended dose is a single intravenous infusion of 5 mg Zoledronic acid. Re-treatment with Zoledronic acid may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, in patients who failed to achieve normalization of serum alkaline phosphatase, or in patients with symptoms, as dictated by medical practice 12 months after the initial dose.

In patients with Paget's disease, adequate Vitamin-D intake is recommended in association with Zoledronic acid administration. In addition, it is strongly advised that adequate supplemental Calcium corresponding to at least 500 mg elemental Calcium twice daily is ensured in patients with Paget's disease for at least 10 days following Zoledronic acid administration.

Zoledronic acid should be administered intravenously via an infusion line, given at a constant infusion rate. The infusion time must not be less than 15 minutes.

Patients with renal impairment
The use of Zoledronic acid in patients with creatinine clearance <35 mL/min is not recommended due to limited clinical safety data in such patients. No dose adjustment is necessary in patients with creatinine clearance >35 mL/min.

Patients with hepatic impairment
No dose adjustment is required for patients with hepatic impairment.

Elderly patients
No dose adjustment is required. However, because decreased renal function occurs more commonly in the elderly, special care should be taken to monitor renal function.

Zoledronic acid must not be mixed or given intravenously with any other medication and must be given through a separate infusion line at a constant infusion rate. If refrigerated, allow the refrigerated solution to reach room temperature before administration. Aseptic techniques must be followed during the preparation of the infusion. Any unused solution should be discarded. Only a clear solutions free from particles and discoloration should be used.

After opening, the solution is chemically and physically stable for at least 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. Zoledronic acid solution for infusion must not be allowed to come into contact with any Calcium or other divalent cation-containing solutions.

The dose of 5 mg Zoledronic acid must be administered over at least 15 minutes.

Side Effects:
The post-dose side-effects are fever, myalgia, flu-like symptoms, arthralgia, and headache, the majority of which occur within the first 3 days following Zoledronic acid administration. The majority of these symptoms were mild to moderate in nature and resolved within 3 days of the event onset. The incidence of these symptoms occurring within the first 3 days after administration of Zoledronic acid, can be reduced with the administration of Paracetamol or Ibuprofen shortly following Zoledronic acid administration. Severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking Zoledronic acid.

Precautions:
Patients must be appropriately hydrated prior to administration of Zoledronic acid. This is especially important in the elderly and for patients receiving diuretic therapy. Adequate hydration can be achieved by the patient drinking two glasses of fluid (such as water) before and after the infusion. Pre-existing hypocalcemia must be treated by adequate intake of Calcium and Vitamin-D before initiating therapy with Zoledronic acid. Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve, thyroid surgery, parathyroid surgery, intestinal Calcium malabsorption). Physicians should consider clinical monitoring for these patients.

Use in Pregnancy & Lactation:
Zoledronic acid is contraindicated during pregnancy and in breastfeeding women. It is also not recommended for use in children and adolescents below 18 years of age.

Drug Interaction:
Specific drug-drug interaction studies have not been conducted with Zoledronic acid. Zoledronic acid is eliminated by renal excretion. Caution is indicated when Zoledronic acid is administered in conjunction with drugs that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration).

Overdose:

Clinical experience with acute overdosage is limited. Patients who have received doses higher than those recommended should be carefully monitored. In the event of overdose leading to clinically significant hypocalcemia, reversal may be achieved with supplemental oral Calcium and/or an infusion of Calcium.

Storage:
Store below 30°C prior to opening. Protect from moisture and light. Zoledronic acid must be kept out of the reach and sight of children.

Zoledronic Acid vial with 4 mg/5 ml: Uses,Dosage,Side Effects

Generic Name
Zoledronic Acid 
Therapeutic Group: Bone and Joint Disorder

Presentation:
Zoledronic acid concentrate for solution for infusion Injection: Each vial with 5 ml concentrate contains Zoledronic acid INN 4 mg (calculated as the anhydrous form, corresponding to 4.265 mg Zoledronic acid monohydrate).

Description:
Zoledronic acid belongs to the class of nitrogen-containing bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic acid is rapidly distributed to the bone. The main molecular target of Zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase, but this does not exclude other mechanisms. Clinical studies in tumour-induced hypercalcemia demonstrated that the effect of Zoledronic acid is characterized by decreases in serum calcium and urinary calcium excretion. In addition to its inhibitory activity against bone resorption, Zoledronic acid also possesses anti-tumour activity, anti-angiogenic activity, anti-pain activity, cytostatic and pro-apoptotic activity on tumour cells, and synergistic cytostatic effect with other anti-cancer drugs. There was no accumulation of the active substance in plasma after multiple doses are given every 28 days. Zoledronic acid is not metabolized and is excreted unchanged via the kidney.

Indications:
• Hypercalcemia of malignancy
• Zoledronic acid is indicated for the treatment & prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone, or surgery to bone) in patients with advanced malignancies involving bone.
• Multiple myeloma and bone metastases of solid tumours
• Zoledronic acid is indicated for the treatment of patients with multiple myeloma and patients with bone metastases from solid tumours (breast cancer, prostate cancer, lung cancer, and other solid tumours) in conjunction with standard antineoplastic therapy.

Dosage & Administration:

Hypercalcemia of malignancy
The maximum recommended dose of Zoledronic acid in hypercalcemia of malignancy (serum calcium 12 mg/dl or 3.0 mmol/l) is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion. Dose adjustment of Zoledronic acid is not necessary for treating patients for hypercalcemia of malignancy presenting with mild to moderate renal impairment. Re-treatment with Zoledronic acid may be considered if serum calcium does not return to normal after initial treatment. It is recommended that a minimum of 7 days elapse before re-treatment, to allow for full response to the initial dose.

Multiple myeloma and bone metastases of solid tumours
The recommended dose of Zoledronic acid in patients with multiple myeloma and metastatic bone lesions from solid tumours is 4 mg infused every 3-4 weeks. Patients should also be administered an oral calcium supplement of 500 mg and 400 IU of Vitamin-D daily.

Patients with renal impairment
The use of Zoledronic acid is not recommended in patients with severe renal impairment (Creatinine clearance <30 ml/min). No dose adjustment is necessary for patients with creatinine clearance >60 ml/min. Based on creatinine clearance the following dose should be used in a patient with impaired renal function –

Reduced doses for patients with baseline creatinine clearance < ml/min

Baseline creatinine clearance (ml/min)Zoledronic acid  Recommended
> 60 4 mg (5 ml)
50 - 60 3.5 mg (4.4 ml)
40 - 49 3.3 mg (4.1 ml)
30 - 39 3 mg (3.8 ml)

Preparation of solution & method of administration
Prior to administration, the required amount of concentrate from one vial must be further diluted with 100 ml of calcium-free infusion solution (0.9 % w/v sodium chloride solution or 5 % w/v glucose solution). The duration of infusion must not be less than 15 minutes. After the addition of the solution to the infusion media, the infusion solution should be used as soon as possible. If storage of the infusion solution is necessary, hold at 2-8 ºC for not more than 24 hours. If refrigerated, the solution must be allowed to reach room temperature before administration.

Zoledronic acid must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer\'s solution, and should be administered as a single intravenous solution in a line separate from all other drugs.

Side Effects:
The post-dose side-effects are headache, nausea, anorexia, fatigue, osteonecrosis of the jaw, anemia, bone pain, constipation, fever, vomiting, flu-like syndrome, hypocalcemia, myalgia, arthralgia, and hypophosphatemia.

Precautions:
Patients must be appropriately hydrated prior to administration of Zoledronic acid. This is especially important in the elderly and for patients receiving diuretic therapy. Adequate hydration can be achieved by the patient drinking two glasses of fluid (such as water) before and after the infusion. Serum levels of calcium, phosphate, magnesium, and potassium, as well as serum creatinine, should be carefully monitored after initiating Zoledronic acid therapy. If hypocalcemia, hypophosphatemia, or hypomagnesemia occurs, short-term supplemental therapy may be necessary. Moreover, careful renal function monitoring should be considered.

Use in Pregnancy & Lactation:
Zoledronic acid is contraindicated during pregnancy and in breastfeeding women. It is also not recommended for use in children and adolescents below 18 years of age.

Drug Interaction:
In clinical studies, Zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics, and analgesics without interactions. Caution is advised when Zoledronic acid is administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium levels for prolonged periods. In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic acid is used in combination with thalidomide. Concomitant use of loop diuretics with Zoledronic acid increases the risk of hypocalcemia. Caution is indicated when Zoledronic acid is used with other potentially nephrotoxic drugs.

Overdose:

Clinical experience with acute overdosage is limited. Overdosage may cause hypocalcemia, hypophosphatemia, and hypomagnesemia. In such cases, reduction in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate respectively.

Storage:

Store below 30 °C prior to opening. Protect from moisture and light. Zoledronic acid must be kept out of the reach and sight of children.

Zolmitriptan: Uses,Dosage,Side Effects

Generic Name
Zolmitriptan
Therapeutic Group: Drugs of Nervous System

Presentation:
Zolmitriptan 2.5 tablet: Each film-coated tablet contains Zolmitriptan INN 2.5 mg.

Indications:
Zolmitriptan 2.5 is indicated for the acute treatment of migraines with or without aura.

Description:
Zolmitriptan is an antimigraine agent. It binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of Zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system which results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Zolmitriptan is rapidly and well absorbed after oral administration.

Dosage & Administration:
The recommended dose of Zolmitriptan to treat a migraine attack is 2.5 mg. If symptoms persist or return within 24 hours, a second dose may be taken not less than 2 hours after the first dose. The maximum dose of Zolmitriptan in 24 hours is 10 mg. Zolmitriptan is equally effective whenever the tablets are taken during a migraine attack; although it is advisable that Zolmitriptan tablets are taken as early as possible after the onset of migraine headache. Patients with hepatic impairment: Patients with moderate or severe hepatic impairment a maximum dose of 5 mg in 24 hours is recommended. Patients with renal impairment: No dosage adjustment required.
Use in children: Safety and efficacy of Zolmitriptan in paediatric patients have not been established.
Use in elderly patients: Safety and efficacy of Zolmitriptan in individuals aged over 65 years have not been systematically evaluated.

Side Effects:
Zolmitriptan is well tolerated. Adverse reactions are typically mild/moderate, transient, not serious and resolve spontaneously without additional treatment. The most commonly reported adverse effects are nausea, dizziness, somnolence, asthenia and dry mouth. Disturbances of sensation have also been reported. Heaviness, tightness, pain or pressure may occur in the throat, neck, limbs and chest (with no evidence of ischaemic changes on ECG).

Precautions:
Zolmitriptan should only be used where a clear diagnosis of migraine has been established. Care should be taken to exclude other potentially serious neurological conditions. There are no data on the use of Zolmitriptan in hemiplegic or basilar migraine. Zolmitriptan should not be given to patients with symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathways. In patients with risk factors for ischaemic heart disease, cardiovascular evaluation prior to commencement of treatment with this class of compounds, including Zolmitriptan, is recommended.

Use in Pregnancy & Lactation:
Pregnancy: There are no studies on pregnant women, but there is no evidence of teratogenicity in animal studies. Zolmitriptan should be used in pregnancy only if the benefits to the mother justify the potential risk to the fetus.
Lactation: No data exists for the passage of Zolmitriptan into human breast milk. Therefore, caution should be exercised when administrating Zolmitriptan to women who are breast-feeding.

Drug Interaction:
There is no evidence that concomitant use of migraine prophylactic medications has any effect on the efficacy or unwanted effects of Zolmitriptan. The pharmacokinetics and tolerability of Zolmitriptan are unaffected by acute symptomatic treatments such as paracetamol, metoclopramide, and ergotamine. However, it is recommended that patients should leave at least 6 hours between taking an ergotamine preparation and starting Zolmitriptan and vice versa. Concomitant administration of other 5-HT1B/1D agonists within 12 hours of Zolmitriptan treatment should be avoided. Following administration of moclobemide, a specific MAO-A inhibitor, there was a small increase in AUC for Zolmitriptan and a 3-fold increase in AUC of the active metabolite. Therefore, a maximum intake of 7.5 mg Zolmitriptan in 24 hours is recommended in patients taking an MAO-A inhibitor.

Over Dose:
There is no experience with clinical overdose. Volunteers receiving single 50 mg oral doses of Zolmitriptan commonly experienced sedation. There is no specific antidote to Zolmitriptan. In case of severe intoxication, intensive care procedures are recommended.

Alprazolam 0.25mg, 0.5 mg, 1mg, 2mg

Generic Name
Alprazolam
Therapeutic Group: Drugs of Nervous System

Indications:
  • Anxiety disorder
  • Short term relief of anxiety
  • Anxiety associated with depression
  • Panic disorder, with or without agoraphobia.
Description:
Alprazolam is a triazole analogue of the 1,4-benzodiazepine class of drugs. It is an anxiolytic with hypnotic and anticonvulsive properties. Alprazolam is presumed to produce its effects via interacting with the Gamma-Aminobutyric Acid (GABA) - benzodiazepine receptor complex. Like all benzodiazepines, it causes a dose-related CNS depressant activity varying from mild impairment of task performance to hypnosis.

Dosage & Administration:
Treatment should be initiated with a dose of 0.25 to 0.5 mg three times daily. Depending on the response, the dose may
be increased at intervals of 3 to 4 days in increments of no more than 1 mg per day. The maximum dose should not
exceed 4 mg/day. Occasional patients with panic disorder may need as much as 10 mg a day to achieve a successful response and in these cases, periodic reassessment and consideration of dosage adjustment are required.
Dosage should be individualized for maximum beneficial effect with the lowest possible dose. If side-effects occur at
starting dose, the dose may be lowered. When discontinuing therapy, dosage should be reduced gradually by no more than 0.5 mg every three days.
In elderly patients or in patients with advanced liver disease, the usual starting dose is 0.25 mg, two or three times daily, and may be gradually increased if needed and tolerated. The safety and effectiveness of Alprazolam in individuals below 18 years of age have not been established.
Lilium XR 1 should be administered once daily, preferably in the morning by patients who are on multiple dosage
regimens of Zolium 0.25/0.5 mg. The tablets should be taken intact, they should not be chewed, crushed, or broken.

Side Effects:
Side effects, if occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. The most frequent side effects are drowsiness and lightheadedness. The other side effects, that may occur include depression, headache, confusion, dry mouth, constipation, etc.

Precautions:
Because Alprazolam may produce psychological and physical dependence, increment of dose or abrupt discontinuation of Alprazolam therapy should not be done without the physician's advice. The duration of therapy must be determined by the physicians. Alprazolam should be administered with caution to patients with hepatic or renal disease, chronic pulmonary insufficiency, or sleep apnea.

Use in Pregnancy & Lactation:
Pregnancy: Alprazolam has been categorized in pregnancy category D; that means, it should be avoided in pregnancy.
Lactation: Like other benzodiazepines, alprazolam is assumed to be excreted in breast milk. Therefore, nursing should not be undertaken by mothers who must use Alprazolam.

Drug Interaction:
The CNS-depressant action of Alprazolam may be aggravated by concomitant use of other psychotropic drugs, anticonvulsants, antihistaminics, alcohol, and oral contraceptives.

Overdose:
Manifestations of Alprazolam overdosage include somnolence, confusion, impaired coordination, diminished reflexes, and coma. In such cases of overdosage general supportive measures should be employed along with immediate gastric lavage.

Storage:
Keep in a dry place far away from light and warmth. exclude the reach of Children's.

(COVID-19) Coronavirus disease

What is COVID-19?
COVID-19 is that the unwellness caused by a brand new coronavirus known as SARS-CoV-2. WHO 1st learned of this new virus on thirty one Gregorian calendar month 2019, following a report of a cluster of cases of ‘viral pneumonia’ in city, People’s Republic of China.

What ar the symptoms of COVID-19?
The most common symptoms of COVID-19 are
  • Fever
  • Dry cough
  • Fatigue
Other symptoms that ar less common and will have an effect on some patients include:
  • Loss of style or smell,
  • Nasal congestion,
  • Conjunctivitis (also called red eyes)
  • Sore throat,
  • Headache,
  • Muscle or joint pain,
  • Different types of efflorescence,
  • Nausea or innate reflex,
  • Diarrhea,
  • Chills or symptom.
Symptoms of severe COVID‐19 unwellness include:
  • Shortness of breath,
  • Loss of appetency,
  • Confusion,
  • Persistent pain or pressure within the chest,
  • High temperature (above thirty eight °C).
Other less common symptoms are:
  • Irritability,
  • Confusion,
  • Reduced consciousness (sometimes related to seizures),
  • Anxiety,
  • Depression,
  • Sleep disorders,
  • More severe and rare neurologic complications like strokes, brain inflammation, delirium and nerve harm.
People of all ages WHO expertise fever and/or cough related to issue respiration or shortness of breath, hurting or pressure, or loss of speech or movement ought to obtain treatment right away. If attainable, decision your health care supplier, hotline or hospice 1st, thus you'll be able to be directed to the proper clinic.

What happens to people that get COVID-19?
Among people who develop symptoms, most (about 80%) get over the unwellness while not having hospital treatment. concerning V-day become seriously sick and need atomic number 8 and five-hitter become critically sick and want medical care.

Complications resulting in death might embrace metabolism failure, acute metabolism distress syndrome (ARDS), infection and septic shock, occlusion, and/or multiorgan failure, as well as injury of the guts, liver or kidneys.

In rare things, youngsters will develop a severe inflammatory syndrome some weeks once infection.

Who is most in danger of severe sickness from COVID-19?
People aged sixty years and over, and people with underlying medical issues like high force per unit area, heart and respiratory organ issues, diabetes, fleshiness or cancer, ar at higher risk of developing serious sickness.

However, anyone will get sick with COVID-19 and become seriously sick or die at any age.

Are there long effects of COVID-19?
Some people that have had COVID-19, whether or not they have required hospitalization or not, still expertise symptoms, as well as fatigue, metabolism and neurologic symptoms.

WHO is functioning with our international Technical Network for Clinical Management of COVID-19, researchers and patient teams round the world to style and do studies of patients on the far side the initial acute course of sickness to know the proportion of patients WHO have future effects, however long they persist, and why they occur. These studies are going to be accustomed develop more steerage for patient care.

How will we tend to shield others and ourselves if we do not recognize WHO is infected?
Stay safe by taking some straightforward precautions, like physical distancing, carrying a mask, particularly once distancing can't be maintained, keeping rooms well louvered, avoiding crowds and shut contact, frequently improvement your hands, and coughing into a bent elbow or tissue. Check native recommendation wherever you reside and work. Do it all!

When ought to i buy a check for COVID-19?
Anyone with symptoms ought to be tested, where doable. UN agency|people that|folks that|those that|those who} don't have symptoms however have had shut contact with somebody who is, or may be, infected can also contemplate testing – contact your native health tips and follow their steerage.

While an individual is watching for check results, they must stay isolated from others. wherever testing capability is restricted, tests ought to initial be in deep trouble those at higher risk of infection, like medical examiners, individuals} at higher risk of severe health problem like older people, particularly those living in seniors’ residences or semipermanent care facilities.


What check ought to i buy to check if I actually have COVID-19?
In most things, a molecular check is employed to observe SARS-CoV-2 and make sure infection. enzyme chain reaction (PCR) is that the most ordinarily used molecular check. Samples ar collected from the nose and/or throat with a swab. Molecular tests observe virus within the sample by amplifying microorganism genetic material to detectable levels. For this reason, a molecular check is employed to substantiate a full of life infection, typically among some days of exposure and round the time that symptoms could begin.

Learn additional regarding what quite COVID-19 tests ar obtainable

What regarding fast tests?
Rapid matter tests (sometimes called a fast diagnostic assay – RDT) observe microorganism proteins (known as antigens). Samples ar collected from the nose and/or throat with a swab. These tests ar cheaper than PCR and can supply results additional quickly, though they're usually less correct. These tests perform best once there's additional virus current within the community and once sampled from a personal throughout the time they're most infectious.

I want to seek out out if I had COVID-19 within the past, what check may I take?
Antibody tests will tell United States of America whether or not somebody has had associate degree infection within the past, though they need not had symptoms. conjointly called serologic tests and typically done on a blood sample, these tests observe associate degreetibodies created in response to an infection. In the majority, antibodies begin to develop when days to weeks and may indicate if an individual has had past infection. protein tests can not be accustomed diagnose COVID-19 within the early stages of infection or unwellness however will indicate whether or not or not somebody has had the unwellness within the past.

What is the distinction between isolation and quarantine?
Both isolation and quarantine ar strategies of preventing the unfold of COVID-19.

Quarantine is employed for anyone WHO could be a contact of somebody infected with the SARS-CoV-2 virus, that causes COVID-19, whether or not the infected person has symptoms or not. Quarantine means you stay separated from others as a result of you have got been exposed to the virus and you will be infected and may turn up during a selected facility or reception. For COVID-19, this implies staying within the facility or reception for fourteen days.

Isolation is employed for folks with COVID-19 symptoms or WHO have tested positive for the virus. Being in isolation suggests that being separated from others, ideally during a medically facility wherever you'll receive clinical care. If isolation during a medical facility isn't doable and you're not during a high risk cluster of developing severe unwellness, isolation will turn up reception. If you have got symptoms, you ought to stay in isolation for a minimum of ten days and a further three days while not symptoms. If you're infected and don't develop symptoms, you ought to stay in isolation for ten days from the time you check positive.



What ought to I do if I actually have been exposed to somebody WHO has COVID-19?
If you have got been exposed to somebody with COVID-19, you will become infected, though you are feeling well.

After exposure to somebody WHO has COVID-19, do the following:
  • Call your health care supplier or COVID-19 hotline to seek out out wherever and once to induce a check.
  • Cooperate with contact-tracing procedures to prevent the unfold of the virus.
  • If testing isn't obtainable, keep home and off from others for fourteen days.
  • While you're in quarantine, don't head to work, to highschool or to public places. raise somebody to bring you provides.
  • Keep a minimum of a 1-metre distance from others, even from your members of the family.
  • Wear a medical mask to safeguard others, as well as if/when you wish to hunt treatment.
  • Clean your hands ofttimes.
  • Stay during a separate space from alternative members of the family, and if inconceivable, wear a medical mask.
  • Keep the space well-ventilated.
  • If you share an area, place beds a minimum of one metre apart.
  • Monitor yourself for any symptoms for fourteen days.
  • Stay positive by keeping in reality with idolized ones by phone or on-line, and by exertion reception.

If you reside in a neighborhood with protozoal infection or dengue, request medical facilitate if you have got a fever. whereas movement to and from the hospice and through treatment, wear a mask, keep a minimum of a 1-metre distance from others and avoid touching surfaces along with your hands. this is applicable to adults and youngsters. scan our protozoal infection and COVID-19 Q&A for additional info.

How long will it want develop symptoms?
The time from exposure to COVID-19 to the instant once symptoms begin is, on average, 5-6 days and may vary from 1-14 days. this is often why people that are exposed to the virus ar suggested to stay reception and be from others, for fourteen days, so as to forestall the unfold of the virus, particularly wherever testing isn't simply obtainable.

Is there a immunogen for COVID-19?
Yes. There square measure 3 COVID-19 vaccines that sure national regulative authorities have approved the utilization. None have nonetheless received World Health Organization EUL/PQ authorization however we tend to expect Associate in Nursing assessment on the Pfizer immunogen by the top of Dec and for a few alternative candidates before long thenceforth.

Large studies of five immunogen candidates effectuality and safety results, as well as these 3 (and for Moderna and AstraZeneca), are in public reported  through press releases however just one (AstraZeneca) has revealed leads to the peer reviewed literature. , we tend to expect additional such reports within the close to future. it's seemingly that further candidates are going to be submitted to regulative authorities for approval. There square measure several potential COVID-19 immunogen candidates presently in development.

Once vaccines square measure incontestible to be safe and efficacious, they have to be approved by national regulators, factory-made to exacting standards, and distributed. World Health Organization is functioning with partners round the world to assist coordinate key steps during this method, as well as to facilitate equitable  access to safe and effective COVID-19 vaccines for the billions of individuals World Health Organization can want them. additional data concerning COVID-19 immunogen development is accessible here

What ought to I do if I even have COVID-19 symptoms?
If you have got any symptoms implicative COVID-19, decision your health care supplier or COVID-19 hotline for directions and decide once and wherever to induce a check, occupy home for fourteen days off from others and monitor your health.

If you have got shortness of breath or pain or pressure within the chest, get medical attention at a consultation room like a shot. decision your health care supplier or hotline before for direction to the correct consultation room.

If you reside in a region with protozoal infection or dandy fever, get treatment if you have got a fever.

If native steerage recommends visiting a medical centre for testing, assessment or isolation, wear a medical mask whereas movement to and from the ability and through treatment. conjointly keep a minimum of a 1-metre distance from people and avoid touching surfaces along with your hands. this is applicable to adults and kids.

Are there treatments for COVID-19?
Scientists round the world square measure operating to seek out and develop treatments for COVID-19.

Optimal substantiative care includes chemical element for severely unwell patients and people World Health Organization square measure in danger for severe illness and additional advanced metabolism support like ventilation for patients World Health Organization square measure critically unwell.

Dexamethasone could be a corticoid which will facilitate scale back the length of your time on a ventilator and save lives of patients with severe and demanding unwellness. scan our corticosteroid Q&A for additional data.

Results from the WHO’s commonness Trial indicated that remdesivir, anti-inflammatory drug, lopinavir/ritonavir and antiviral regimens seem to own very little or no impact on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.

Hydroxychloroquine has not been shown to supply any profit for treatment of COVID-19. scan our anti-inflammatory drug Q&A for additional data.

WHO doesn't advocate self-medication with any medicines, as well as antibiotics, as a interference or cure for COVID-19. World Health Organization is coordinating  efforts to develop treatments for COVID-19 and can still give new data because it becomes obtainable.

Are antibiotics effective in preventing or treating COVID-19?
Antibiotics don't work against viruses; they solely work on microorganism infections. COVID-19 is caused by a deadly disease, therefore antibiotics don't work. Antibiotics shouldn't be used as a way of interference or treatment of COVID-19.

In hospitals, physicians can typically use antibiotics to forestall or treat secondary microorganism infections which might be a complication of COVID-19 in severely unwell patients. they must solely be used as directed by a MD to treat a microorganism infection.

information collected:-https://www.who.int/

WHO validates Cote d’Ivoire for eliminating sleeping sickness as a public health problem

Côte d'Ivoire has with success eliminated human African trypanosomiasis, conjointly called “sleeping sickness”, as a public ill-health, turning into the second African country when Togo to be valid by the planet Health Organization (WHO).


“I dedicate this milestone to decades of toil and therefore the individual contribution of every single doctor WHO braved a number of the toughest challenges in reaching populations, typically in remote rural areas,” same Dr Aka Aouele, Minister of Health and Public Hygiene of an African nation. “Our challenge now could be to take care of the desired level of police work and, with the assistance of everybody, to attain interruption of transmission by 2030.”

In the Nineties, African nation rumored many cases of cephalitis each year. Cases have more and more declined over the last a pair of decades, and within the past few years, the country has rumored fewer than ten cases each year. At this low level, African nation qualifies as having eliminated the sickness as a public ill health.

This action is attributed to strong management and police work measures, active (and passive) screening of individuals in danger, and targeted vector management, that helped to powerfully decrease the quantity of cases in areas of transmission. Hospitals and health centres checked patients victimisation specific diagnostic tests, whereas laboratory mobile units screened folks in villages.

“Côte d’Ivoire’s action marks a vital step that brings continent nearer to eliminating cephalitis,” same Dr Matshidiso Moeti, WHO Regional Director for continent. “Sustained management measures over the past a pair of decades have brought a major decline in cases – a positive sign that a lot of countries can shortly be crossing this landmark.”

Treatment of infected folks meant that the vector – the tsetse – might now not transmit the sickness to others. This had to be maintained over years so as to more and more eliminate the sickness.


"The result that African nation has achieved when many decades of fighting against human African Trypanosomiasis, reflects the wonderful leadership of the Ministry of Health and Public Hygiene through the board of directors of the HAT Elimination Programme” same Dr Jean Marie Vianny Yameogo, WHO Representative in African nation.” it's conjointly the expression of the commitment and determination of the regional and division health directorates, health professionals, the communities' participation up to the mark methods and therefore the vitality of the partnership.

Two different countries – African nation and Spanish Guinea – have submitted their dossiers to WHO, requesting validation for elimination of cephalitis as a public health problem1.

Under WHO’s leadership, national management programmes, bilateral cooperation agencies and nongovernmental organizations have well reduced cases of the sickness to unprecedented low numbers – specifically but one thousand globally – before 2020.

Sleeping sickness may be a probably fatal sickness unfold by the bite of AN infected tsetse, a species native to the African continent. over sixty million folks living chiefly in rural elements of thirty six countries across East, Central and area unita|geographic area|geographical region|geographic region} are in danger of acquiring the sickness.

Validation for elimination of a public ill health

The validation for every country is assessed by WHO. a whole written record should be submitted to gift elaborated info on the past and gift sickness incidence throughout the territory. The country should show proof of effective, in progress police work to prove that the capability of police work the sickness is powerful. The figures should be below the precise thresholds needed by WHO – that's below one case per ten 000 inhabitants altogether districts – throughout a 5-year amount.

WHO and partners square measure targeting the interruption of transmission of the Trypanosoma brucei gambiense sort of the sickness altogether endemic countries by 2030.

The main approaches to dominant cephalitis embrace reducing the reservoirs of infection and reducing the presence of the tsetse.

Screening of individuals in danger helps establish patients throughout the first stage of the sickness. If diagnosing is formed early, it's potential to avoid sophisticated and risky treatment procedures throughout the advanced stage.

The sickness

Human African trypanosomiasis may be a vector-borne parasitic sickness caused by infection with protozoan parasites happiness to the genus Trypanosoma. The borne in upon parasite is transmitted to humans through the bite of a tsetse (Glossina genus) that has nonheritable the infection from humans or animals harbouring the human unhealthful parasites.

There square measure a pair of kinds of the disease: one thanks to the gambiense trypanosome, that is found in twenty four countries in West and Central African Republic and accounts for over ninety eight of cases; and another thanks to Trypanosoma brucei rhodesiense, that is found in thirteen countries in East and Southern continent and accounts for the remaining cases.

When bitten by AN infected tsetse, a red sore could erupt among a number of weeks. The person could expertise fever, swollen humour nodes, aching muscles and joints, headaches and irritability.

People who become infected feel unergetic and sleepy-eyed throughout the day, then awake however exhausted at nighttime. this can be followed by medicine and sensory disorders, and so a coma. Death could occur among months or perhaps years.

1 a whole written record should be submitted to gift elaborated info on the past and gift sickness incidence throughout the territory. The country should show proof of effective, in progress police work to prove that the capability of police work the sickness is powerful. The figures should be below the precise thresholds needed by WHO, which suggests one case per ten 000 inhabitants altogether districts, throughout a five-year amount. https://www.who.int/

WHO announces 2nd edition Health for All Film Festival shortlist and jury composition

In a rare demonstration of artistic energy and enthusiasm for telling public health stories, the second edition of the Health for All festival has attracted nearly 1200 short film submissions - each amateur and skilled - from one hundred ten countries. These have currently been shortlisted to fifteen to sixteen titles in every of the 3 competition categories: Universal Health Coverage, Health emergencies, and higher health and well-being.

“Telling stories is as previous as human civilisation », aforementioned United Nations agency Director-General Dr Tedros Adhanom Ghebreyesus. “It helps to inspire, motivate, build sympathy and share issues therefore we are able to notice and share solutions along. Everything United Nations agency will is regarding stories, as a result of everything we have a tendency to do is regarding folks. We’re excited regarding the number and quality of entries during this year’s Health for All festival. Ultimately, we have a tendency to hope the pageant isn't simply the simplest way to inform stories, however to alter the arc of people’s stories round the world, towards higher health.”

The shortlisted films is viewed by the general public as of nowadays through Youtube playlists on the market on the Festival’s web site furthermore as WHO’s Youtube channel. the general public is invited to post comments and queries on the short films and a range of those queries are featured throughout on-line award ceremonies in could.

The following distinguished professionals, artists and activists have in agreement to hitch four United Nations agency senior specialists to create the pageant jury: Eugenio Derbez (Actor from Mexico); Dr Leyla Hussein (Psychotherapist from African nation and activist on gender rights); Martin Fernando Jakobsen (Director of organisation Turning Tables from Danmark, and activist for youth empowerment); Sonia Lowman (Documentary director from USA), Milica Momcilovic (President of World Federation of Science Journalists, from Serbia); and Vithika Yadav (Human rights activist from India).

In the returning weeks, jurors can review the shortlisted films and suggest winners to WHO’s Director-General, United Nations agency can build the ultimate call.

Three “GRAND PRIX” are declared on thirteen could throughout a group discussion followed by a series of on-line ceremonies with winners and jurors.

WHO additionally plans to award 3 special prizes: a student-produced film, a health instructional film aimed toward youth, and a Health Equity Film to pay tribute to the theme of the planet Health Day campaign in 2021.

For additional details on the official choice, the jury composition and additional data, visit https://www.who.int/film-festival

Cefuroxime Axetil: Uses,Dosage,Side Effects

Generic Name                                                 বাংলায় দেখুন
Cefuroxime Axetil
Therapeutic Class: Antimicrobial drugs (Second-generation Cephalosporins)

Indications:
It is indicated for the treatment of infections caused by sensitive bacteria.
  • Pharyngitis/Tonsillitis caused by Streptococcus pyogenes.
  • Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase-producing strains), or Streptococcus pyogenes.
  • Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase producing strains)
  • Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli
  • Acute bacterial exacerbation of chronic bronchitis and Secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains).
  • Skin and skin structure infections are caused by Staphylococcus aureus (including beta-lactamase-producing strains) or Streptococcus pyogenes.
  • Urinary tract infections are caused by E.coli or Klebsiella pneumoniae.
  • Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).
  • Gonorrhea is caused by penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae.
  • Early Lyme Disease (erythema migrans) is caused by Borrelia burgdorferi.
Description:
Cefuroxime may be a well-characterized and effective bactericide agent, that has broad-spectrum antiseptic activity against a good vary of common pathogens, as well as manufacturing strains. Mefoxin has smart stability to microorganisms and consequently, is active against several ampicillin-resistant and Amoxycillin-resistant strains.

Dosage & Administration:
Tablet or Suspension-
Adolescents and adults (13 years and older)-
  • Pharyngitis/tonsillitis: 250 mg b.i.d. for 5-10 days
  • Acute microorganism jaw sinusitis: 250 mg b.i.d. for ten days
  • Acute microorganism exacerbation of chronic bronchitis: 250-500 mg b.i.d. for ten days
  • Secondary microorganism infections of acute bronchitis: 250-500 mg b.i.d. for 5-10 days
  • Uncomplicated skin and skin structure infections: 250-500 mg b.i.d. for ten days
  • Uncomplicated tract infections: 250 mg b.i.d. for 7-10 days
  • Uncomplicated Gonorrhoea: one thousand mg Single dose
  • Community nonheritable pneumonia: 250-500 mg b.i.d. for 5-10 days
  • MDR enteric fever Fever: five hundred mg b.i.d. for 10-14 days
  • Early Lyme disease: five hundred mg b.i.d. for twenty days
Pediatric Patients (3 months to 12 years)-
  • Pharyngitis/Tonsillitis: twenty mg/kg/day b.i.d for 5-10 days
  • Acute redness media: thirty mg/kg/day b.i.d for ten days
  • Acute microorganism jaw sinusitis: thirty mg/kg/day b.i.d for ten days
  • Impetigo: thirty mg/kg/day b.i.d for ten-day
Parenteral-
  • Adult: 750 mg thrice daily by IM or IV injection. In severe infections, doses are often increased up to one.5 metric weight units thrice daily by IV injection. The frequency could also be increased to fourfold daily, if necessary, giving total daily doses of three to six gms.
  • Children (above three months of age): thirty - a hundred mg/kg/day given in three or four equally divided doses. A dose of sixty mg/kg/day is suitable for many infections.
  • Neonate: thirty - a hundred mg/kg/day given in a pair of or three equally divided doses.
  • Surgical prophylaxis: one.5 metric weight unit by IV injection at induction of anesthesia; up to three doses of 750 mg could also be given by IV/IM injection every eight hours for top risk procedures.
  • Pneumonia: one.5 metric weight unit IV injection double daily for 2-3 days, followed by five hundred mg double daily (oral) for 7-10 days.
  • Acute exacerbations of chronic bronchitis: 750 mg double daily (IM or IV injection) for 2-3 days, followed by five hundred mg double daily (oral) for 5-10 days. (Duration of each channel and oral medical aid is set by the severity of the infection and also the clinical standing of the patient.)
  • In Gonorrhoea: Adult: one.5 metric weight unit as one dose (as a pair of x 750mg injections intramuscularly with totally different sites, e.g. every buttock).
In Meningitis:
  • Adult: three metric weight unit IV injection thrice daily.
  • Children (above three months of age): 200-240 mg/kg/day by IV injection in three or four divided doses reduced to a hundred mg/kg/day once three days or on clinical improvement.
  • Neonate: a hundred mg/kg/day by IV injection at initial dose, reduced to fifty mg/kg/day, once clinically indicated. 
In bone and joint infections:
  • Adult: 1.5 metric weight unit IV injection fourfold daily.
  • Children (above three months of age): a hundred and fifty mg/kg/day (not to exceed the utmost adult dose) in equally divided doses every eight hours.
Administration: The use of freshly reconstituted resolution is usually recommended. However, it maintains efficiency for a minimum of twenty-four hours at temperature or forty-eight hours at 5o C

Interaction:
No, doubtless risky interactions are according.

Contraindications:
Cefuroxime is contraindicated in patients with acknowledged hypersensitivity reaction to Cephalosporins.

Side Effects:
Adverse effects to Mefoxin have occurred sometimes and are typically gentle and transient in nature. Effects according to embrace rashes and channel disturbances. like different antibiotics, prolonged use could lead to the overgrowth of non-inclined organisms e.g. Candida.

Pregnancy & Lactation:
US office physiological state class of Mefoxin is B. There are, however, no adequate and well-controlled studies in pregnant girls. as a result of animal, replica studies aren't invariably prophetic of human response, this drug ought to be used throughout the physiological state given that clearly required. Mefoxin is shown to be excreted in human milk. So, caution ought to be exercised once Mefoxin is run to a nursing lady.

Precautions & Warnings: 
Cefuroxime ought to tend with care to patients receiving coincident treatment with potent diuretics & the UN agency has a history of inflammatory bowel disease. Mefoxin antibiotics could generally tend safely to patients UN agency area unit allergic to antibiotic drug though cross-reactions have according. Mefoxin has shown, that's unlikely to be a drag at the suggested dose levels.

Reconstitution:
For 750 mg contractor injection: Add three-milliliter water for injection to ampoule so shake gently for dispersion.
For 750 mg blood vessel injection: Add eight-milliliter water for injection to ampoule so shake gently for dispersion. the answer ought to be slowly injected directly into a vein over a three to five minutes amount.
For 1.5 g blood vessel injection: Add sixteen milliliter Water for injection to ampoule so shake gently for dispersion. the answer ought to be slowly injected directly into a vein over a three to five minutes amount.

Storage :
Store in a very cool, dry place (below 30o C), aloof from light-weight & wet. keep of the reach of kids.

Brand Names

Brand Name

Company

Strength 

Axim

Aristopharma Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial

Turbocef

Beximco Pharmaceuticals Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial
Kilbac

Incepta Pharmaceuticals Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial

Cefotil

Square Pharmaceuticals Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial
Sefur

Opsonin Pharma Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial
Cefobac

Popular Pharmaceuticals Ltd.

250 mg+500 mg+125 mg/5 ml 750 mg/vial,1.5 gm/vial


Cefixime Trihydrate: Uses,Dosage,Side Effects

Generic Name                                                বাংলায় দেখুন
Cefixime Trihydrate
Therapeutic Class: Third Generation Cephalosporins

Indications:
Cefixime is indicated within the treatment of the subsequent infections once caused by the prone strains of the selected microorganisms:
  • Uncomplicated tract infections caused by E. coli and Proteus Mirabilis.
  • Otitis Media is caused by Haemophilus influenzae, Moraxella catarrhalis, and streptococci pyogenes.
  • Pharyngitis and rubor are caused by streptococci pyogenes.
  • Acute respiratory disease and acute exacerbations of bronchitis caused by streptococci pneumonia and Haemophilus influenza.
  • Uncomplicated Cupid's itch (cervical/urethral) caused by gonococcus.
Description:
Cefixime could be a third-generation synthetic antibiotic drug antibiotic for oral administration. it's a disinfectant against a broad spectrum of gram-positive and gram-negative microorganisms at simply realizable plasma concentrations. It kills microorganisms by being busy within the synthesis of microorganism semipermeable membrane. it's extremely stable within the presence of a penicillinase accelerator. As a result, several organisms immune to penicillins and a few cephalosporins thanks to the presence of beta-lactamases, are also prone to Cefixime. Absorption of it's regarding four-hundredth to five hundredths whether or not administered with or while not food.

Dosage & Administration:
The usual course of treatment is seven days. this might be continued for up to fourteen days reckoning on the severity of the infection.

Adult and youngsters over twelve years: The suggested adult dose is a pair of00-400 mg (1 to 2 capsules) daily, given either as one dose or in 2 divided doses. For the treatment of uncomplicated cervical/urethral gonococcal infections, one oral dose of Cefixime four hundred mg is suggested.

Children (6 months or older): sometimes eight mg/kg/day given as one dose or in 2 divided doses or is also given as following
  • ½-1 year: seventy-five mg daily.
  • 1-4 years: a hundred mg daily.
  • 5-10 years: two hundred mg daily.
  • 11-12 years: three hundred mg daily
  • In typhoid, the dose ought to be ten mg/kg/day for fourteen days.
Children (under half a dozen months): the protection and effectiveness of Cefixime have not been established in kids aged but half a dozen months.

Interaction:
Carbamazepine: Concomitant use elevates the carbamazepine level. anticoagulant and different anticoagulants: Concomitant use will increase clotting factor time.

Contraindications:
It is contraindicated in hypersensitivity to Cefixime or different cephalosporins.

Side Effects:
The drug is mostly well tolerated. the foremost frequent aspect effects area unit symptom and stool changes; that is a lot of ordinarily related to higher doses. different aspect effects area unit nausea, abdominal pain, dyspepsia, vomiting, flatulence, headache, and lightheadedness. Allergies within the type of rash, pruritus, urticaria, drug fever, and hurting are reportable. These reactions sometimes subsided upon discontinuation of medical aid.

Pregnancy & Lactation:
There are, however, no adequate and well-controlled studies in pregnant ladies. as a result of animal, copy studies don't seem to be forever prophetical of human response, this drug ought to be used throughout physiological conditions as long as clearly required. it's not identified that Cefixime is excreted in human milk. So, caution ought to be exercised once Cefixime is run to a nursing lady.

Precautions & Warnings:
The drug ought to be prescribed with caution in people with a history of channel malady, significantly inflammatory bowel disease. The drug ought to be with caution in patients with marked impaired excretory organ operation moreover as those undergoing continuous ambulant serous membrane chemical analysis and dialysis. dose adjustment is simply necessary in severe kidney disease (creatinine clearance < twenty ml/min), therein case a dose of two hundred mg once daily mustn't be exceeded.

Overdose :
Gastric Lavage is also indicated; otherwise, no specific remedy exists. Cefixime isn't removed in vital quantities from the circulation by dialysis or serous membrane chemical analysis. Adverse reactions in little numbers of healthy adult volunteers receiving single doses up to a pair of g of Cefixime didn't dissent from the profile seen in patients treated at the suggested doses.

Storage :
Keep below 30ºC temperature, shielded from light-weight & wet. shut off the reach of kids.

Brand Names

Brand Name

Company

Strength 

Afix

Aristopharma Ltd.

200 mg+400 mg

Triocim

Beximco Pharmaceuticals Ltd.

200 mg+400 mg
Emixef

Incepta Pharmaceuticals Ltd.

200 mg+400 mg

Cef-3

Square Pharmaceuticals Ltd.

200 mg+400 mg
Ceftid

Opsonin Pharma Ltd.

200 mg+400 mg
CeximeGlaxoSmithKline

200 mg+400 mg


Ciprofloxacin: Uses, Dosage, Side Effects

Generic Name                                              বাংলায় দেখুন
Ciprofloxacin
Therapeutic Class: 4-Quinolone preparations, Anti-diarrhoeal Antimicrobial medicine

Pharmacology:
Ciprofloxacin is also an artificial fluoroquinolone. it's disinfectant activity against an honest vary of gram-positive and gram-negative organisms. It inhibits microorganism desoxyribonucleic acid synthesis by binding with the microorganism enzyme-DNA gyrase and topoisomerase IV that a square measure to blame for desoxyribonucleic acid supercoiling.

Indications:
Ciprofloxacin is indicated for the treatment of tract Infections, Urinary tract infections, girdle Inflammatory Diseases, Infectious symptoms (Shigella dysenteriae, vibrion cholera), typhoid, Intra-abdominal infections, inflammation, Skin, and Soft Tissue Infections, Bone and Joint Infections, Gonorrhea, Neutropenic patients with fever because of microorganism infection, Meningitis, Surgical bar.

Dosage:
Tablet: 
Adult:
  • Respiratory Tract Infections: 500 to 750 mg doubly daily (7 to fourteen days)
  • Urinary tract infections: 250 to 750 mg doubly daily (3 to ten days)
  • Pelvic Inflammatory Diseases: 500 to 750 mg doubly daily (14 days)
  • Infectious symptom (Shigella dysenteriae, vibrion cholera): five hundred mg doubly daily (1 to 5 days)
  • Typhoid fever: 500 mg doubly daily (7 days)
  • Intra-abdominal infections: 500 to 750 mg doubly daily (5 to fourteen days)
  • Prostatitis: five hundred to 750 mg doubly daily (2 to 6 weeks)
  • Skin and Soft Tissue Infections: 500 to 750 mg doubly daily (7 to fourteen days)
  • Bone and Joint Infections: 500 to 750 mg doubly daily (max. 3 months)
  • Gonorrhea: 500 mg united dose
  • Neutropenic patients with fever because of microorganism infection: 500 to 750 mg doubly daily co-administered with acceptable antibacterials.
  • Meningitis: 500 mg united dose.
  • Surgical prophylaxis: 500 mg united dose, an hour before the procedure.
Suspension: Pediatric:
10-20 mg/kg (max. 750 mg) doubly daily (10 to twenty-one days). The length of medical aid depends on the type and severity of the infection.

Extended unharness tablet: In uncomplicated tract infection (acute cystitis), the suggested dose of extended unharness pill is one thousand mg pill once daily for three days.

For IV infusion:
  • Urinary Tract Infection: delicate to Moderate: two hundred mg twelve hourly for 7-14 days; Severe or Complicated: four hundred mg twelve hourly for 7-14 days
  • Lower tract infection: delicate to Moderate: four hundred mg twelve hourly for 7-14 days; Severe or Complicated: four hundred mg eight hourly for 7-14 days
  • Nosocomial Pneumonia: Mild/Moderate/Severe: four hundred mg eight hourly for 10-14 days
  • Skin and Skin Structure: delicate to Moderate: four hundred mg twelve hourly for 7-14 days; Severe or Complicated: four hundred mg eight hourly for 7-14 days
  • Bone and Joint Infection: delicate to Moderate: four hundred mg twelve hourly for quite 4-6 weeks; Severe/Complicated: four hundred mg eight hourly for quite 4-6weeks
  • Intraabdominal (Acute abdomen): Complicated: four hundred mg twelve hourly for 7-14 days
  • Acute Sinusitis: Mild/Moderate: four hundred mg twelve hourly for ten days
  • Chronic microorganism Prostatitis: Mild/Moderate: four hundred mg twelve hourly for twenty-eight Days.
Administration:
Instruction for the use of Cipro IV infusion-
  • Check the bag for minute leaks by squeeze the inner bag firmly. If leaks square measure found, or if seal is not intact, discard the solution.
  • Insert piercing pin of administration set into port with a twisting motion till the pin is firmly sitting.
  • Suspend bag from the hanger.
  • Squeeze and unharness drip chamber to work out correct fluid level in the chamber throughout the infusion of Cipro IV infusion.
  • Do not use if the solution is cloudy or a precipitate is a gift.
  • Do not use versatile baggage serial connections.
  • Close flow management clamp of administration set.
  • Remove cowl from the port inside of the bag.
  • Open flow management clamp to expel air from set.Close clamp.
  • Regulate rate of administration with flow management clamp
Duration of treatment: The length of treatment depends upon the severity of infection, clinical response, and medicine findings. For acute infections, the quality treatment amount is five to ten days. typically treatment ought to be continuing for three days once the signs and symptoms of the infection square measure disappeared.

Interaction:

Concurrent administration of Cipro ought to be avoided with metal or metal-containing antacids or medicament or with a different product containing metallic element, Iron, or metal. This product might even be taken 2 hours once or six hours before Cipro. Cipro should not be taken at the same time with milk or different dairy farm product, since absorption of Cipro might even be considerably reduced. The dietary metallic element is also a vicinity of a meal, however, does not considerably have an effect on the absorption of Cipro.

Contraindications:
It is contraindicated in patients World Health Organization has famous hypersensitivity to Cipro or different quinolones.

Side Effects:

Side effects include- nausea and different gi disturbances, headache, dizziness, joint pain, and skin rashes.

Pregnancy & Lactation:
There don't seem to be adequate and well-controlled studies in pregnant ladies. Cipro ought to be used throughout gestation as long because the potential profit justifies the potential risk to the vertebrate and mother. Cipro is excreted in human milk. because of the potential risk of articulary injury, Cipro should not be used throughout lactation.

Precautions & Warnings:
Patients receiving Cipro ought to be schooled to drink fluids munificently. It ought to be used with caution in patients with suspected or famous system disorders like encephalopathy or different factors that incline to seizures and convulsion. Avoid in patients with famous QT prolongation, symptoms.

Use in Special Populations:
Although effective in clinical trials, Cipro is not a drug of initial alternative in the pediatric population.

Overdose :
Overdose following Cipro administration might cause seizures, hallucinations, confusion, abdominal discomfort, urinary organ, and viscus impairment conjointly as crystalluria, haematuria, & reversible urinary organ toxicity.

Storage:
Keep below 30°C temperature, protected from lightweight & wetness. exclude of the reach of kids.

Brand Names

Brand Name

Company

Strength 

Aprocin

Aristopharma Ltd.

250 mg+500 mg+750 mg

Neofloxin

Beximco Pharmaceuticals Ltd.

250 mg+500 mg+750 mg
Beuflox

Incepta Pharmaceuticals Ltd.

250 mg+500 mg+750 mg

Ciprocin

Square Pharmaceuticals Ltd.

250 mg+500 mg+750 mg
Ciprox

Opsonin Pharma Ltd.

250 mg+500 mg+750 mg
Civox

Popular Pharmaceuticals Ltd.

1250 mg+500 mg+750 mg